Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease

Thorax

Volumn 65, Issue 6, 2010, Pages 559-570

  Milburn, Heather ^a   Ashman, Neil ^b   Davies, Peter ^c   Doffman, Sarah ^d   Drobniewski, Francis ^b   Khoo, Saye ^e   Ormerod, Peter ^f   Ostermann, Marlies ^g   Snelson, Catherine ^h  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d BRIGHTON GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^g GUY S HOSPITAL   (United Kingdom)

^h West Midlands Deanery Emergency Medicine Rotation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; CORTICOSTEROID; CYCLOSPORIN; ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; KANAMYCIN; MOXIFLOXACIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; STREPTOMYCIN; TACROLIMUS; TUBERCULOSTATIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; BRAIN DISEASE; CHEMOPROPHYLAXIS; CHRONIC KIDNEY DISEASE; CONFUSION; CONTINUOUS RENAL REPLACEMENT THERAPY; DEPRESSIVE PSYCHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG WITHDRAWAL; ENZYME ASSAY; GOUT; GRAFT REJECTION; GRAND MAL SEIZURE; HALLUCINATION; HEMODIALYSIS; HUMAN; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; JAUNDICE; KIDNEY TRANSPLANTATION; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NIGHTMARE; OTOTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SIDE EFFECT; THORAX RADIOGRAPHY; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULIN TEST; TWITCHING MOTILITY; VOMITING; ADULT; ANTIBIOTIC PROPHYLAXIS; CHRONIC KIDNEY FAILURE; EVIDENCE BASED MEDICINE; LATENT TUBERCULOSIS; MASS SCREENING; METHODOLOGY; OPPORTUNISTIC INFECTION; RENAL REPLACEMENT THERAPY; TUBERCULOSIS;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTITUBERCULAR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; LATENT TUBERCULOSIS; MASS SCREENING; OPPORTUNISTIC INFECTIONS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; TUBERCULOSIS;

EID: 77953725205     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.133173     Document Type: Review

References (113)

1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. (l+).
2. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUALTD trial. Bull World Health Organ 1982;60:555-64. (2++).
3. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. Short course rifampicin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicentre clinical trial. Ann Intern Med 2002;137:640-7. (l-).
4. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a seven year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-18. (2+).
5. Bailey EC, Taylor SL, Dascomb HE, et al. Disturbed hepatic function during isoniazid chemoprophylaxis. Am Rev Respir Dis 1973;107:523-9. (2+).
6. Hong Kong Chest Service, Tuberculosis Research Centre Madras, and British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41. (l++).
7. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008;149:689-97. (1-).
8. Lee AM, Mennone JZ, Jones RC, et al. Risk factors for hepatotoxicity associated with rifampicin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002;6:995-1000. (2+).
9. Stout JE, Engemann JJ, Cheng AC, et al. Safety of two months rifampicin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167:824-7. (2+).
10. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005;60:800-5. (l-).
11. Kay NE, Raij LR. Immune abnormalities in renal failure and hemodialysis. Blood Purif 1986;4:120-9. (2++).
12. Gibbons RAS, Martinez OM, Garovoy MR. Altered monocyte function in uraemia. Clin Immunol Immunopathol 1990;56:66-71. (2+).
13. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. (l+).
14. Lundin AP, Adler AJ, Berlyne GM, et al. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 1979;67:597-602. (3).
15. Chia S, Karim M, Elwood RK, et al. Risk of tuberculosis in dialysis patients: a population-based study. Int J Tuberc Lung Dis 1998;2:989-91. (3).
16. Andrew OT, Schoenfeld PY, Hopewell PC, et al. Tuberculosis in patients with endstage renal disease. Am J Med 1980;68:59-65. (3).
17. The National Collaborating Centre for Chronic Conditions. Tuberculosis. Clinical diagnosis and management of tuberculosis and measures for its prevention and control. March 2006. http://www.nice.org.uk/nicemedia/pdf/ CG033FullGuideline.pdf. (l++).
18. CDC and MMWR. Targeted tuberculin testing and treatment of latent tuberculosis infection. 9 June 2000/Vol. 49/No. RR-6. http://www.cdc.gov/mmwr/ PDF/rr/rr4906.pdf. (l-).
19. Aguado HM, Torre-Cisneros J, Fortun J, et al. Tuberculosis in solid-organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009;48:1276-84. (l-).
20. Smirnoff M, Patt G, Seckler R, et al. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. Chest 1998;113:25-7 (2-).
21. Shankar MS, Aravindan AN, Sohal PM, et al. The prevalence of tuberculin sensitivity and anergy in chronic renal failure in an endemic area: tuberculin test and the risk of post-transplant tuberculosis. Nephrol Dial Transplant 2005;20:2720-4. (2+).
22. Poduval RD, Hammes MD. Tuberculosis screening in dialysis patients: is the tuberculin test effective? Clin Nephrol 2003;59:436-40. (2+).
23. Woeltje KF, Mathew A, Rothstein M, et al. Tuberculosis infection and anergy in hemodialysis patients. Am J Kidney Dis 1998;31:848-52. (2-).
24. Wojnar RJ, Brittain RJ, Dzelzkalns E. Effect of nonsteroidal anti-inflammatory and other pharmacological agents on tuberculin reaction. J Pharm Sci 1979;68:12-15. (2+).
25. Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006;12:744-51. (l+).
26. Amedia C, Oettinger CW. Unusual presentation of tuberculosis in chronic hemodialysis patients. Clin Nephrol 1977;8:363-6. (3).
27. Lightstone L. Preventing renal disease: the ethnic challenge in the United Kingdom. Kidney Int 2003;63:S135-8. (2++).
28. Yuan FH, Guang LX, Zhao SJ. Clinical comparisons of 1,498 chronic renal failure patients with and without tuberculosis. Ren Fail 2005;27:149-53. (2+).
29. Rutsky EA, Rostand SG. Mycobacteriosis in patients with chronic renal failure. Arch Intern Med 1980;140:57-61. (3).
30. Ahmed AT, Karter AJ. Tuberculosis in California dialysis patients. Int J Tuberc Lung Dis 2004;8:341-5. (2-).
31. Sen N, Turenc T, Karatasli M, et al. Tuberculosis in patients with end-stage renal disease undergoing dialysis in an endemic region of Turkey. Transplant Proc 2008;40:81-4. (3).
32. Quantrill SJ, Woodhead MA, Bell CE, et al. Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2001;16:1024-7. (3).
33. Malik GH, Al-Harbri AS, Al-Mohaya S, et al. Eleven years of experience with dialysis associated tuberculosis. Clin Nephrol 2002;58:356-62. (3).
34. Riska H, Gronhagen-Riska C, Ahonen J. Tuberculosis and renal allograft transplantation. Transplant Proc 1987;19:4096-7. (2+).
35. McWhinney N, Khan O, Williams G. Tuberculosis in patients undergoing maintenance haemodialysis and renal transplantation. Br J Surg 1981;68:408-11. (3).
36. Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983;5:216-26. (3).
37. Lloveras J, Peterson PK, Simmons RL, et al. Mycobacterial infections in renal transplant recipients. Seven cases and a review of the literature. Arch Intern Med 1982;142:888-92. (3).
38. Ergun I, Ekmekci Y, Sengul S, et al. Mycobacterium tuberculosis infection in renal transplant recipients. Transplant Proc 2006;38:1344-5. (3).
39. Atasever A, Bacakoglu F, Toz H, et al. Tuberculosis in renal transplant recipients on various immunosuppressive regimens. Nephrol Dial Transplant 2005;20:797-802. (2+).
40. Abbott KC, Klote MM. Update on guidelines for prevention and management of Mycobacterium tuberculosis infections after transplant. Am J Transplant 2005;5 (5):1163. (l+).
41. Queipo JA, Broseta E, Santos M, et al. Mycobacterial infection in a series of 1261 renal transplant recipients. Clin Microbiol Infect 2003;9:518-25. (3).
42. Vandermarliere A, Van Audenhove A, Peetermans WE, et al. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis 2003;5:9-15. (3).
43. Chen CH, Lian JD, Cheng CH, et al. Mycobacterium tuberculosis infection following renal transplantation in Taiwan. Transpl Infect Dis 2006;8:148-56. (3).
44. Agarwal DK, Dash SC, Tiwari SC, et al. Spectrum of tuberculosis in renal transplant recipients in northern India. Indian J Nephrol 1992;2:39-43. (3).
45. Sakhuja V, Jha V, Verma PP, et al. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996;61:211-15. (3).
46. Hariharan S, Date A, Gopalkrishnan G, et al. Tuberculosis after renal transplantation. Dialysis Transpl 1987;16:311-12. (3).
47. John GT, Shankar V. Mycobacterial infections in organ transplant recipients. Semin Respir Infect 2002;17:274-83. (2++).
48. Basiri A, Moghaddam SM, Simforoosh N, et al. Preliminary report of a nationwide case-control study for identifying risk factors of tuberculosis following renal transplantation. Transplant Proc 2005;37:3041-4. (2+).
49. Zhang XF, Lv Y, Xue WJ, et al. Mycobacterium tuberculosis infection in solid organ transplant recipients: experience from a single centre in China. Transplant Proc 2008;40:1382-5. (3).
50. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009;33:956-73. (l+).
51. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34. (2+).
52. Passalent LKK, Richardson R, Wang J, et al. Detecting latent tuberculosis infection in haemodialysis patients: a head to head comparison of the T-SPOT TB test, tuberculin skin test and an expert physician panel. Clin J Am Soc Nephrol 2007;2:68-73. (2+).
53. Winthrop KL, Nyendak M, Calvet H, et al. Interferon-γ release assays for diagnosing Mycobacterium tuberculosis infection in renal dialysis patients. Clin J Am Soc Nephrol 2008;3:1357-63. (2+).
54. Triverio PA, Bridevaux PO, Roux-Lombard P, et al. Interferon-gamma release assays versus tuberculin skin testing for detecting of latent tuberculosis in chronic haemodialysis patients. Nephrol Dial Transplant 2009;24:2186-9. (2+).
55. Lee SS, Chou KJ, Su IJ, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on haemodialysis: Comparison of QuantiFERONTB GOLD, ELISPOT and tuberculin skin test. Infection 2009;37:96-102. (2+).
56. American Thoracic Society and Centres for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47. (2++).
57. Centres for Disease Control. Fatal and severe hepatitis associated with rifampicin and pyrazinamide for the treatment of latent tuberculosis infection - New York and Georgia, 2000. MMWR Morbidity Mortality Weekly Report 2001;50:289-91. (2++).
58. Centres for Disease Control. Update: Fatal and severe liver injuries associated with rifampicin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations - United States 2001. MMWR Morbidity Mortality Weekly Report 2001;50:733-5. (2++).
59. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis: recommendations 2000. Thorax 2000;55: 887-901. (2++).
60. Vikrant S, Agarwal SK, Gupta S, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005;7:99-108. (1+).
61. Agarwal SK, Gupta S, Dash SC, et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipients. Int Urol Nephrol 2004;36:425-31. (l+).
62. Sayiner A, Ece T, Duman S, et al. Tuberculosis in renal transplant recipients. Transplantation 1999;68:1268-71. (3).
63. Yildiz A, Sever MS, Turkmen A, et al. Tuberculosis after renal transplantation: experience of one Turkish centre. Nephrol Dial Transplant 1998;13:1872-5. (3).
64. Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 1999;(1):CD001363. Cochrane Library, 2010, Issue 1. (l+).
65. Kumar D, Watson JM, Charlett A, et al. Tuberculosis in England and Wales in 1993: results of a national survey. Thorax 1997;52:1060-7. (2+).
66. th century in England and Wales: results of a national survey in 1998. Thorax 2001;56: 173-9. (2+).
67. Pozniak A, Ormerod JP, Miller R. Treatment of tuberculosis in HIV-infected patients. AIDS 1999:13:435-45. (4).
68. Ormerod P, Novelli V, Pozniak A, et al. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998;53:536-48. (l+).
69. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-22. (2++).
70. Kenny MT, Strates B. Metabolism and pharmacokinetics of the antibiotic rifampin. Drug Metab Rev 1981;12:159-218. (2++).
71. Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984;9:511-44. (2++).
72. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuberc Lung Dis 1996;77:37-42. (3).
73. Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 1999;159:1580-4. (2+).
74. Quantrill SJ, Woodhead MA, Bell CE, et al. Side-effects of antituberculosis drug treatment in patients with chronic renal failure. Eur Respir J 2002;20:440-3. (3).
75. Cheung WC, Lo CY, Lo WK, et al. Isoniazid induced encephalopathy in dialysis patients. Tuber Lung Dis 1993;74:136-9. (3).
76. Siskind MS, Thienemann D, Kirlin L. Isoniazid-induced neurotoxicity in chronic dialysis patients: report of three cases and a review of the literature. Nephron 1993;64:303-6. (3).
77. Wang HY, Chien CC, Chen YM, et al. Encephalopathy caused by isoniazid in a patient with end stage renal disease with extrapulmonary tuberculosis. Ren Fail 2003;25:135-8. (3).
78. Blumberg EA, Gil RA. Cerebellar syndrome caused by isoniazid. DICP 1990;24:829-31. (3).
79. Altiparmak MR, Pamuk ON, Pamuk GE, et al. Is isoniazid ototoxic in patients undergoing hemodialysis? Nephron 2002;92:478-80. (3).
80. Shaheen FA, Mansuri NA, al-Shaikh AM, et al. Reversible uremic deafness: is it correlated with the degree of anemia? Ann Otol Rhinol Laryngol 1997;106:391-3. (2+).
81. Gendeh BS, Gibb AG, Aziz NS, et al. Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol Head Neck Surg 1998;118:551-8. (2-).
82. Manian FA, Stone WJ, Alford RH. Adverse antibiotic effects associated with renal insufficiency. Rev Infect Dis 1990;12:236-49. (2++).
83. Ellard GA. Chemotherapy of tuberculosis for patients with renal impairment. Nephron 1993;64:169-81. (2++).
84. East African/British Medical Research Council. Isoniazid with thiacetazone in the treatment of pulmonary tuberculosis in East Africa: Second investigation. Tubercle 1963;44:301-33. (2+).
85. Acocella G, Mattiussi R, Segre G. Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week. Pharmacol Res Commun 1978;10:271-88. (2+).
86. Rekha VV, Santha T, Jawahar MS. Rifampicin-induced renal toxicity during retreatment of patients with pulmonary tuberculosis. J Assoc Physicians India 2005;53:811-13. (3).
87. Lacroix C, Hoang TP, Nouveau J, et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 1989;36:395-400. (2+).
88. Ellard GA. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 1969;50:144-58. (2+).
89. Stamatakis G, Montes C, Trouvin JH, et al. Pyrazinamide and pyrazinoic acid pharmacokinetics in patients with chronic renal failure. Clin Nephrol 1988;30:230-4. (2+).
90. Peets EA, Sweeney WM, Place VA, et al. The absorption, excretion and metabolic fate of ethambutol in man. Am Rev Respir Dis 1965;91:51-8. (2++).
91. Lee CS, Gambertoglio JG, Brater DC, et al. Kinetics of oral ethambutol in the normal subject. Clin Pharmacol Ther 1977;22:615-21. (2+).
92. Lee CS, Brater DC, Gambertoglio JG, et al. Disposition kinetics of ethambutol in man. J Pharmacokinet Biopharm 1980;8:335-46. (2+).
93. Varughese A, Brater DC, Benet LZ, et al. Ethambutol kinetics in patients with impaired renal function. Am Rev Respir Dis 1986;134:34-8. (2+).
94. Citron K. Ethambutol: a review with special reference to ocular toxicity. Tubercle 1969;50(Suppl):32-6. (2++).
95. Line DH, Poole GW, Waterworth PM. Serum streptomycin levels and dizziness. Tubercle 1970;51:76-81. (3).
96. Matzke GR, Halstenson CE, Keane WF. Hemodialysis elimination rates and clearance of gentamicin and tobramycin. Antimicrob Agents Chemother 1984;25:128-30. (3).
97. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Drugs 2002;62:2169-83. (l+).
98. Panchagnula R, Kaur KJ, Singh I, et al. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO. Int J Tuberc Lung Dis 1999;3(11 Suppl 3):S336-42; discussion S351-2. (2++).
99. Burman WJ, Goldberg S, Johnson JC, et al. Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-8. (l). (Pubitemid 44156613)
100. Rustomjee R, Lienhardt C, Kanyok T, et al. Gatifloxacin for TB (OFLOTUB) study team. A phase II study of the sterilising activity of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-38. (1+).
101. Mehlhorn AJ, Brown DA. Safety concerns with fluoroquinolones. Ann Pharmacother 2007;41:1859-66. (l+).
102. Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clin Pharmacokinet 2005;44:221-35. (l-). (Pubitemid 40477786)
103. Ahn C, Oh K-H, Kim K, et al. Effect of peritoneal dialysis on plasma and peritoneal fluid concentrations of isoniazid, pyrazinamide and rifampicin. Perit Dial Int 2003;23:362-7. (2-).
104. EBPG Expert Group in Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient; V.7.2 Late infections. Tuberculosis. Nephrol Dial Transplant 2002;17(Suppl 4):39-43. (l-).
105. Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc 2003;35:2449-51. (3).
106. Chenhsu RY, Loong CC, Chou MH, et al. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. Ann Pharmacother 2000;34:27-31. (3).
107. Baxter K ed. Stockley's drug interactions (electronic version). London: Pharmaceutical Press, 2008. (l+).
108. Kuypers DR, Verleden G, Naesens M, et al. Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphophate-glucuronosyltransferase. Clin Pharmacol Ther 2005;78:81-8. (3).
109. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19. (l+).
110. Zhu M, Nix DE, Adam RD, et al. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001;21:891-7. (l+).
111. Malone RS, Fish DN, Spiegel DM, et al. The effect of hemodialysis on cycloserine, ethionamide, para-aminosalicylate, and clofazimine. Chest 1999;116: 984-90. (2+).
112. Holdiness MR. Neurological manifestations and toxicities of the antituberculosis drugs. A review. Med Toxicol 1987;2:33-51. (l-).
113. Berns JSBM. Drug prescribing in renal failure: dosing guidelines for adults. 4th edn. Philadelphia, PA: American College of Physicians, 1999. (l+).